Subtype
Liver Neoplasm
CI-CAN-00001077Explore in graph →
Non-malignant930 active trials14 approved drugs17 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001077Explore in graph →
Clinical trials
4,331 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06369597 | A Randomized Controlled Trial of the Safety and Efficacy of Robotic Telesurgery Versus Laparoscopic Surgery | unknown | N/A | 177 | Sun Yat-sen UniversityOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT06370065 | Serplulimab Combined With Bevacizumab Biosimilar and HAIC in Advanced Hepatocellular Carcinoma (HCC) Patients | unknown | Phase 2 | 35 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 17, 2024 |
| NCT06363123 | Plasma Metabolic Biomarkers for Multi-Cancer Diagnosis | unknown | — | 2,700 | Beijing Friendship HospitalOTHER | 1 | Apr 15, 2024 | clinicaltrials |
| NCT06365034 | Study on the Efficacy and Safety of Conversion Therapy in Patients With Initially Unresectable Hepatocellular Carcinoma | unknown | — | 92 | Qianfoshan HospitalOTHER | 1 | Apr 15, 2024 | clinicaltrials |
| NCT06061445 | Radiotherapy Combined With TKI and Anti-PD-1 Antibody for Stage IIIA Hepatocellular Carcinoma | unknown | N/A | 22 | Fujian Cancer HospitalOTHER_GOV | 1 | Apr 12, 2024 | clinicaltrials |
| NCT06364007 | HAIC Combined With Durvalumab and Tremelimumab and Lenvatinib in uHCC | unknown | Phase 2 | 20 | Sulai LiuOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT06356623 | A Risk Prediction Model of Postoperative Nausea and Vomiting in Patients With Liver Cancer | unknown | — | 476 | Shanghai Zhongshan HospitalOTHER | 0 | Apr 10, 2024 | clinicaltrials |
| NCT06355700 | Hepatocellular Carcinoma Liver Organoids(HELIO) | unknown | N/A | 10 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Apr 9, 2024 | clinicaltrials |
| NCT06342323 | The Optimal Number of Fiducial Marker for Stereotactic Body Radiotherapy(ONFM-SBRT) | unknown | — | 57 | Peking University Third HospitalOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT05626985 | Refinement and Validation of a Diagnostic Model (GAMAD) for Early Detection of Hepatocellular Carcinoma | unknown | — | 2,000 | Singlera Genomics Inc.INDUSTRY | 1 | Apr 1, 2024 | clinicaltrials |
| NCT06335927 | HAIC Combined With Cadonilimab and Regorafenib as 2nd-line Treatment for ICC | unknown | Phase 2 | 45 | Fudan UniversityOTHER | 1 | Mar 28, 2024 | clinicaltrials |
| NCT06325267 | Clinical Characteristics of Primary Liver Cancer | unknown | — | 1,000 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Mar 27, 2024 | clinicaltrials |
| NCT05767697 | Genomics and Prognosis in GI Cancers | unknown | — | 1,000 | National Health Research Institutes, TaiwanOTHER | 1 | Mar 26, 2024 | clinicaltrials |
| NCT06328283 | The Diagnostic Efficacy of Glutamine Synthetaseand BCLAF1in Early Diagosis of Hepatocellular Carcinoma in Cirrhotic Patients | unknown | — | 90 | Sohag UniversityOTHER | 1 | Mar 25, 2024 | clinicaltrials |
| NCT05783570 | To Evaluate the Safety, Tolerability and Preliminary Efficacy of EU307 | unknown | Phase 1 | 12 | EutilexINDUSTRY | 1 | Mar 15, 2024 | clinicaltrials |
| NCT06304766 | Open Versus Laparoscopic Ablation of Liver Malignancies(OPTIMAL) | unknown | N/A | 80 | Rigshospitalet, DenmarkOTHER | 1 | Mar 13, 2024 | clinicaltrials |
| NCT04605185 | Donafenib and Toripalimab Combined With TACE in Patients With Unresectable Hepatocellular Carcinoma | unknown | Phase 1 | 18 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Mar 6, 2024 | clinicaltrials |
| NCT04780217 | Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 42 | ImmVira Pharma Co. LtdINDUSTRY | 1 | Mar 4, 2024 | clinicaltrials |
| NCT05124002 | Recombinant Human Adenovirus Type 5 Plus HAIC of FOLFOX for Intrahepatic Cholangiocarcinoma | unknown | Phase 4 | 66 | Beijing Tsinghua Chang Gung HospitalOTHER | 1 | Mar 4, 2024 | clinicaltrials |
| NCT05637788 | Artificial Intelligence and Hepatocellular Carcinoma(ARTIHCC) | unknown | — | 535 | Humanitas Clinical and Research CenterOTHER | 1 | Mar 4, 2024 | clinicaltrials |
| NCT06289712 | Evaluation of the Ablation of Hepatic Lesions by Electroporation(EVALHEP) | unknown | — | 50 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Mar 4, 2024 | clinicaltrials |
| NCT06285019 | Modified TOMOX-HAIC in Combination With Sintilimab and Bevacizumab Biosimilar for First-line Treatment of Advanced Hepatocellular Carcinoma | unknown | Phase 2 | 65 | Fudan UniversityOTHER | 1 | Feb 29, 2024 | clinicaltrials |
| NCT05531864 | Ultrasound-guided Continuous Low Serratus Anterior Plane Block in Hepatocellular Carcinoma Surgery(RCT) | unknown | N/A | 160 | Liu DiOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT06278701 | The Effect of Late-evening Snacks on Patients With Primary Hepatocellular Carcinoma After Hepatectomy | unknown | N/A | 106 | DU YaoOTHER | 1 | Feb 26, 2024 | clinicaltrials |
| NCT06075849 | Phase I Study to Evaluate Safety and Anti-tumor Activity of PB101, an Anti-angiogenic Immunomodulating Agent | unknown | Phase 1 | 30 | Panolos BioscienceINDUSTRY | 1 | Feb 23, 2024 | clinicaltrials |
| NCT05178043 | GT90001 Plus Nivolumab in Patients With Advanced Hepatocellular Carcinoma | unknown | Phase 2 | 5 | Suzhou Kintor Pharmaceutical Inc,INDUSTRY | 1 | Feb 22, 2024 | clinicaltrials |
| NCT05924997 | Adebrelimab, Camrelizumab Plus Apatinib as First-line Therapy in Patients With Advanced Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 52 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Feb 21, 2024 | clinicaltrials |
| NCT06271109 | Short Term Surgical Outcomes of Anatomical Versus Non Anatomical Laparoscopic Liver Resection for Liver Tumors | unknown | — | 50 | Sohag UniversityOTHER | 1 | Feb 21, 2024 | clinicaltrials |
| NCT03474822 | Plasmodium Immunotherapy for Breast and Liver Cancers | unknown | Phase 1 / Phase 2 | 60 | CAS Lamvac Biotech Co., Ltd.INDUSTRY | 1 | Feb 20, 2024 | clinicaltrials |
| NCT06210334 | HAIC Combine Tislelizumab and Lenvatinib in the Treatment of HCC With Type IV (Vp4) Portal Vein Tumor Thrombus (HAI-TL)(HAI-TL) | unknown | Phase 2 | 54 | Li Xiao WeiOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT06148155 | A Study of [68Ga]Ga-NOTA-RG2 PET Imaging in the Diagnosis of Hepatocellular Carcinoma | unknown | N/A | 20 | Huashan HospitalOTHER | 1 | Feb 16, 2024 | clinicaltrials |
| NCT05829057 | The IIT Study of Evaluation of P-IL-2 Single Agent and With Anti-PD-1 | unknown | Phase 1 | 10 | Zhejiang UniversityOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT05028933 | IMC001 for Clinical Research on Advanced Digestive System Malignancies | unknown | Phase 1 | 48 | Zhejiang UniversityOTHER | 1 | Feb 12, 2024 | clinicaltrials |
| NCT05842317 | Lenvatinib Plus Tislelizumab With or Without TACE in First-line Treatment of Unresectable HCC | unknown | Phase 1 / Phase 2 | 60 | Peking Union Medical College HospitalOTHER | 1 | Feb 9, 2024 | clinicaltrials |
| NCT05173298 | Predictive Biomarkers in Patients With Advanced Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab(HCC) | unknown | — | 100 | CHA UniversityOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT06247293 | Surgical Resection Combined With Intraperitoneal Hyperthermic Chemotherapy | unknown | — | 100 | Zhujiang HospitalOTHER | 0 | Feb 7, 2024 | clinicaltrials |
| NCT06031818 | Usability and Clinical Effectiveness of an Interpretable Deep Learning Framework for Post-Hepatectomy Liver Failure Prediction | unknown | — | 80 | Maastricht UniversityOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT06244446 | Efficacy and Safety of SBRT Combined With Atezolizumab Plus Bevacizumab vs Atezolizumab Plus Bevacizumab in Treating Unresectable Advance Hepatocellular Carcinoma. | unknown | — | 40 | Institute of Liver and Biliary Sciences, IndiaOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT04161287 | Comparison of Efficacy in SBRT of HCC ≤5 cm With or Without TACE | unknown | — | 330 | Beijing 302 HospitalOTHER | 1 | Feb 2, 2024 | clinicaltrials |
| NCT04560894 | SCT-I10A Plus SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma(HCC) | unknown | Phase 2 / Phase 3 | 405 | Sinocelltech Ltd.INDUSTRY | 1 | Feb 1, 2024 | clinicaltrials |
| NCT04682847 | Radiotherapy With Iron Oxide Nanoparticles (SPION) on MR-Linac for Primary & Metastatic Hepatic Cancers | unknown | — | 40 | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)OTHER | 1 | Jan 31, 2024 | clinicaltrials |
| NCT06233994 | A Study Evaluating the Efficacy and Safety of ZG005 in Combination With Donafenib or Bevacizumab in Patients With Advanced Hepatocellular Carcinoma | unknown | N/A | 30 | Changsha Taihe HospitalOTHER_GOV | 1 | Jan 31, 2024 | clinicaltrials |
| NCT05062837 | Hepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCC | unknown | Phase 2 / Phase 3 | 62 | Guangxi Medical UniversityOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT05711823 | Aprepitant Plus Granisetron and Dexamethasone for the Prevention of Vomiting in Patients With HAIC Therapy for HCC | unknown | Phase 3 | 300 | Guangxi Medical UniversityOTHER | 0 | Jan 23, 2024 | clinicaltrials |
| NCT05910970 | Adjuvant Tislelizumab Plus Lenvatinib for Patients at High-risk of HCC Recurrence After Curative Resection or Ablation(PREVENT-2) | unknown | Phase 3 | 200 | Guangxi Medical UniversityOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT06182644 | Head-to-head Comparison of Positron Nuclide Radio-labeled FAPI and 18F-FDG PET/CT in Patients With Malignant Tumors(FAPI) | unknown | N/A | 30 | Guangdong Provincial People's HospitalOTHER | 1 | Jan 22, 2024 | clinicaltrials |
| NCT04224480 | Longitudinal Immune-phenotyping of HCC Following MK-3475 | unknown | Phase 1 | 8 | National Cancer Centre, SingaporeOTHER | 1 | Jan 19, 2024 | clinicaltrials |
| NCT05293158 | Impact of Hepatitis B Immunoglobulins in Patients With Chronic Hepatitis B on Hepatocellular Carcinoma - a Proof of Concept Study(HBIG) | unknown | N/A | 5 | Medical University of GrazOTHER | 0 | Jan 18, 2024 | clinicaltrials |
| NCT04800497 | The Role Of Circulating Tumor Cells As Markers Of Advanced Disease And Prognosis In HCC | unknown | — | 70 | University of Milano BicoccaOTHER | 1 | Jan 17, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Apr 17, 2024source: clinicaltrials